1% Tavilermide Ophthalmic Solution

DRUG2 trials

Sponsors

Mimetogen Pharmaceuticals USA, Inc.

Conditions

Keratoconjunctivitis Sicca

Phase 3

A Safety and Efficacy Study of Tavilermide (MIM-D3) Ophthalmic Solution for the Treatment of Dry Eye

CompletedNCT02634853

Mimetogen Pharmaceuticals USA, Inc.Keratoconjunctivitis Sicca

Start: 2015-12-31End: 2017-03-31Updated: 2019-08-16

A Safety and Efficacy Study of Tavilermide (MIM-D3) Ophthalmic Solution for the Treatment of Dry Eye Disease

CompletedNCT02665234

Mimetogen Pharmaceuticals USA, Inc.Keratoconjunctivitis Sicca

Start: 2016-01-31End: 2017-03-31Updated: 2019-08-16